LeMaitre Vascular, Inc. $LMAT Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. cut its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 4.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 290,673 shares of the medical instruments supplier’s stock after selling 13,883 shares during the period. Envestnet Asset Management Inc. owned about 1.28% of LeMaitre Vascular worth $25,437,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. First Trust Advisors LP grew its stake in LeMaitre Vascular by 52.7% during the 2nd quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock valued at $50,829,000 after purchasing an additional 211,280 shares in the last quarter. Millennium Management LLC boosted its stake in shares of LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after buying an additional 115,141 shares during the last quarter. Grandeur Peak Global Advisors LLC acquired a new stake in shares of LeMaitre Vascular during the second quarter worth approximately $6,275,000. Goldman Sachs Group Inc. increased its stake in shares of LeMaitre Vascular by 27.0% in the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock worth $22,019,000 after buying an additional 55,804 shares during the last quarter. Finally, Geneva Capital Management LLC raised its holdings in LeMaitre Vascular by 6.0% in the second quarter. Geneva Capital Management LLC now owns 915,238 shares of the medical instruments supplier’s stock valued at $76,010,000 after acquiring an additional 51,489 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Weiss Ratings reiterated a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Monday, December 29th. Cantor Fitzgerald reissued a “neutral” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research report on Monday, November 10th. Roth Mkm reaffirmed a “buy” rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, November 5th. Finally, Wall Street Zen lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $100.20.

LeMaitre Vascular Trading Down 1.3%

Shares of NASDAQ:LMAT opened at $86.60 on Friday. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44. The company’s 50-day moving average price is $84.76 and its 200 day moving average price is $87.82. The company has a market cap of $1.96 billion, a PE ratio of 37.33, a P/E/G ratio of 1.95 and a beta of 0.72. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $105.55.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.